CCC Live Cases > COVID > P2Y12 Inhibitor Monotherapy after PCI: The TWILIGHT Study and Recent Lancet Meta-Analysis

P2Y12 Inhibitor Monotherapy after PCI: The TWILIGHT Study and Recent Lancet Meta-Analysis

Moderator: Roxana Mehran, MD

Samin Sharma, MD
Annapoorna Kini, MD
George Dangas, MD
Usman Baber, MD
Giulio Stefanini, MD
Mauro Chiarito, MD
Valentin Fuster, MD

1:03:05

Comments

Leave a Reply

Your email address will not be published.*


Warning: Invalid argument supplied for foreach() in /home/468933.cloudwaysapps.com/wrezgzxbge/public_html/wp-content/plugins/constant-contact-forms/includes/class-settings.php on line 1087

Yes, I would like to receive emails from Mount Sinai Hospital. Sign me up!


By submitting this form, you are consenting to receive marketing emails from: Mount Sinai Hospital, One Gustave L. Levy Place, Box, New York, NY, 10029, https://ccclivecases.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact